We are currently recruiting participants for the following studies:

Schizophrenia - Cognitive Behavioral Therapy (CBT)

This study is seeking volunteers who experience unusual thinking or delusions for a clinical trial to improve symptoms. Participants take add-on d-cycloserine or placebo while receiving twelve weeks of cognitive behavior therapy and are compensated for their time.

Eligibility:

  • 18 - 68 years old
  • Diagnosed with schizophrenia or schizoaffective disorder 

PI: Faith Dickerson, PhD, MPH

Sponsor: Sheppard Pratt Health System (Coordinating site: New York University School of Medicine)

To participate, email Cassie Stallings, R.N., or call 410-938-4356.

Learn more about this study.


Schizophrenia - Cognitive Functioning

This study is seeking volunteers for a clinical trial that may improve cognitive functioning. 

Participants take add-on valacyclovir or placebo for sixteen weeks and are compensated for their time. 

Eligibility:

  • 18 - 40 years old
  • Diagnosed with Schizophrenia or Schizoaffective Disorder within the past eight years

PI: Faith Dickerson, PhD, MPH

Sponsor: Sheppard Pratt Health System (Coordinating site: Indiana University)

To participate, email Cassie Stallings, R.N., or call 410-938-4356.

Learn more about this study.


Bipolar Disorder

This study is an Open-Label study of Transcranial Magnetic Stimulation (TMS) in patients with Bipolar Disorder who are currently depressed.

We are currently seeking participants ages 18 and older to enroll in this outpatient study.

PI: Scott Aaronson, M.D.

Sponsor: Sheppard Pratt Health System

To participate in this study, email Brittany Troen or call 410-938-3139.

Learn more about this study.


Major Depressive Disorder

This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.

We are currently seeking participants ages 18 to 65 to enroll in this outpatient study.

PI: Scott Aaronson, M.D.

Sponsor: Sheppard Pratt Health System/Otsuka Pharmaceutical Development & Commercialization, Inc.

To participate in this study, email Brittany Troen or call 410-938-3139.

Learn more about this study.